D W Hein


Affiliation: University of Louisville
Country: USA


  1. request reprint
    Hein D, Leff M, Ishibe N, Sinha R, Frazier H, Doll M, et al. Association of prostate cancer with rapid N-acetyltransferase 1 (NAT1*10) in combination with slow N-acetyltransferase 2 acetylator genotypes in a pilot case-control study. Environ Mol Mutagen. 2002;40:161-7 pubmed
    ..This finding should be investigated further in larger cohorts and in other ethnic populations. ..
  2. Hein D, Fretland A, Doll M. Effects of single nucleotide polymorphisms in human N-acetyltransferase 2 on metabolic activation (O-acetylation) of heterocyclic amine carcinogens. Int J Cancer. 2006;119:1208-11 pubmed
    ..05) decreased catalytic activity towards the O-acetylation of N--OH--MeIQx but not N--OH--PhIP. These results have important implications towards the interpretation of molecular epidemiological studies of NAT2 genotype and cancer risk. ..
  3. Hein D, Boukouvala S, Grant D, Minchin R, Sim E. Changes in consensus arylamine N-acetyltransferase gene nomenclature. Pharmacogenet Genomics. 2008;18:367-8 pubmed publisher
    ..louisville.edu. New NAT alleles should continue to be submitted to the NAT Nomenclature Committee for inclusion on the website to ensure proper categorization and to continue consistency in nomenclature. ..
  4. Hein D. N-acetyltransferase 2 genetic polymorphism: effects of carcinogen and haplotype on urinary bladder cancer risk. Oncogene. 2006;25:1649-58 pubmed
  5. Hein D, Kidd L. Design and Success of a 21st Century Cancer Education Program at the University of Louisville. J Cancer Educ. 2018;33:298-308 pubmed publisher
    ..Our cancer education program will continue to enhance the professional development of the next generation of cancer scientists and clinicians. ..
  6. Zhang X, Carlisle S, Doll M, Martin R, States J, Klinge C, et al. High N-Acetyltransferase 1 Expression Is Associated with Estrogen Receptor Expression in Breast Tumors, but Is not Under Direct Regulation by Estradiol, 5α-androstane-3β,17β-Diol, or Dihydrotestosterone in Breast Cancer Cells. J Pharmacol Exp Ther. 2018;365:84-93 pubmed publisher
    ..Clusters of high-expression genes, including NAT1, in breast tumors might serve as potential targets for novel therapeutic drug development. ..
  7. request reprint
    Loehle J, Cornish V, Wakefield L, Doll M, Neale J, Zang Y, et al. N-acetyltransferase (Nat) 1 and 2 expression in Nat2 knockout mice. J Pharmacol Exp Ther. 2006;319:724-8 pubmed
    ..The Nat2 KO model will be useful in future studies to assess the role of Nat2 in arylamine carcinogenesis. ..
  8. Hein D, Bendaly J, Neale J, Doll M. Systemic functional expression of N-acetyltransferase polymorphism in the F344 Nat2 congenic rat. Drug Metab Dispos. 2008;36:2452-9 pubmed publisher
    ..These congenic rat lines are useful for investigating the role of NAT2 genetic polymorphisms in susceptibility to cancers related to arylamine carcinogen exposures. ..
  9. Hein D. N-acetyltransferase SNPs: emerging concepts serve as a paradigm for understanding complexities of personalized medicine. Expert Opin Drug Metab Toxicol. 2009;5:353-66 pubmed
    ..As medical care moves to a more personalized approach, the implications of these confounding factors will be important in understanding the complexities of personalized medicine. ..

More Information


  1. Stepp M, Doll M, Samuelson D, Sanders M, States J, Hein D. Congenic rats with higher arylamine N-acetyltransferase 2 activity exhibit greater carcinogen-induced mammary tumor susceptibility independent of carcinogen metabolism. BMC Cancer. 2017;17:233 pubmed publisher
    ..01). A novel role for rat NAT2 in mammary cancer was discovered unrelated to carcinogen metabolism, suggesting a role for human NAT1 in breast cancer. ..
  2. Doll M, Hein D. Genetic heterogeneity among slow acetylator N-acetyltransferase 2 phenotypes in cryopreserved human hepatocytes. Arch Toxicol. 2017;91:2655-2661 pubmed publisher
    ..These results further support phenotypic heterogeneity among NAT2 slow acetylator genotypes, consistent with differential risks of drug failure or toxicity and cancer associated with carcinogen exposure. ..
  3. Hein D, Doll M. Catalytic properties and heat stabilities of novel recombinant human N-acetyltransferase 2 allozymes support existence of genetic heterogeneity within the slow acetylator phenotype. Arch Toxicol. 2017;91:2827-2835 pubmed publisher
    ..05) higher than NAT2 4. These results provide further evidence of genetic heterogeneity within the NAT2 slow acetylator phenotype. ..
  4. Hein D, Doll M. Rabbit N-acetyltransferase 2 genotyping method to investigate role of acetylation polymorphism on N- and O-acetylation of aromatic and heterocyclic amine carcinogens. Arch Toxicol. 2017;91:3185-3188 pubmed publisher
    ..The new NAT2 genotyping method facilitates use of the rabbit model to investigate the role of acetylator polymorphism in the metabolism of aromatic and heterocyclic amine drugs and carcinogens. ..
  5. Allen C, Doll M, Hein D. N-Acetyltransferase 2 Genotype-Dependent N-Acetylation of Hydralazine in Human Hepatocytes. Drug Metab Dispos. 2017;45:1276-1281 pubmed publisher
    ..Our results clearly document NAT2 genotype-dependent N-acetylation of hydralazine in human hepatocytes, suggesting that hydralazine efficacy and safety could be improved by NAT2 genotype-dependent dosing strategies. ..
  6. Hein D, Zhang X, Doll M. Role of N-acetyltransferase 2 acetylation polymorphism in 4, 4'-methylene bis (2-chloroaniline) biotransformation. Toxicol Lett. 2018;283:100-105 pubmed publisher
    ..In conclusion, our results show that NAT2 acetylator genotype has an important role in MOCA metabolism and suggest that risk assessments related to MOCA exposures consider accounting for NAT2 acetylator phenotype in the analysis. ..